AMICUS THERAPEUTICS, INC. Total Liabilities
AMICUS THERAPEUTICS, INC. had Total Liabilities of $675.63 million as of 2025-12-31, per its 10-K filed 2026-02-20.
Financial Statements › Balance Sheet › Liabilities
us-gaap:Liabilities · last filed 2026-02-20
- 2025-12-31: Liabilities $675.63M.
- 2025-09-30: Liabilities $638.39M.
- 2025-06-30: Liabilities $611.00M.
- 2025-03-31: Liabilities $596.28M.
| Period end | Liabilities |
|---|---|
| 2025-12-31 | $675.63M 10-K · filed 2026-02-20 |
| 2025-09-30 | $638.39M 10-Q · filed 2025-11-04 |
| 2025-06-30 | $611.00M 10-Q · filed 2025-07-31 |
| 2025-03-31 | $596.28M 10-Q · filed 2025-05-01 |
| 2024-12-31 | $590.99M 10-K · filed 2026-02-20 |
| 2024-09-30 | $607.73M 10-Q · filed 2024-11-06 |
| 2024-06-30 | $616.96M 10-Q · filed 2024-08-08 |
| 2024-03-31 | $591.10M 10-Q · filed 2024-05-09 |
| 2023-12-31 | $617.71M 10-K · filed 2025-02-19 |
| 2023-09-30 | $630.85M 10-Q · filed 2023-11-08 |
| 2023-06-30 | $618.51M 10-Q · filed 2023-08-08 |
| 2023-03-31 | $597.95M 10-Q · filed 2023-05-10 |
| 2022-12-31 | $601.12M 10-K · filed 2024-02-28 |
| 2022-09-30 | $626.96M 10-Q · filed 2022-11-07 |
| 2022-06-30 | $627.16M 10-Q · filed 2022-08-04 |
| 2022-03-31 | $588.32M 10-Q · filed 2022-05-10 |
| 2021-12-31 | $597.77M 10-K · filed 2023-03-01 |
| 2021-09-30 | $580.05M 10-Q · filed 2021-11-09 |
| 2021-06-30 | $572.98M 10-Q · filed 2021-08-05 |
| 2021-03-31 | $559.14M 10-Q · filed 2021-05-10 |
| 2020-12-31 | $600.14M 10-K · filed 2022-02-24 |
| 2020-09-30 | $580.27M 10-Q · filed 2020-11-05 |
| 2020-06-30 | $340.50M 10-Q · filed 2020-08-10 |
| 2020-03-31 | $335.75M 10-Q · filed 2020-05-07 |
| 2019-12-31 | $373.78M 10-K · filed 2021-03-01 |
| 2019-09-30 | $334.02M 10-Q · filed 2019-11-12 |
| 2019-06-30 | $317.98M 10-Q · filed 2019-08-08 |
| 2019-03-31 | $313.03M 10-Q · filed 2019-05-09 |
| 2018-12-31 | $447.04M 10-K · filed 2020-03-02 |
| 2018-09-30 | $427.64M 10-Q · filed 2018-11-05 |
| 2018-06-30 | $263.99M 10-Q · filed 2018-08-07 |
| 2018-03-31 | $348.39M 10-Q · filed 2018-05-09 |
| 2017-12-31 | $274.17M 10-K · filed 2019-02-28 |